ArticleAdvanced healthcare materials2017
Preprogrammed Long-Term Systemic Pulsatile Delivery of Parathyroid Hormone to Strengthen Bone.
Article in Advanced healthcare materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Parathyroid Hormone Modulates Alveolar Bone Metabolism via Inducing Periodontal Ligament Stem Cells Aerobic Glycolysis.International dental journal · 2026Article
- Pulsatile Release of Human Gonadotropin Releasing Hormone Using a Photoactivated Depot Containing an Unusual Light Cleaved Functionality.Molecular pharmaceutics · 2026Article
- An Integrated Microcurrent Delivery System Facilitates Human Parathyroid Hormone Delivery for Enhancing Osteoanabolic Effect.Small methods · 2025Article
- Dual release scaffolds as a promising strategy for enhancing bone regeneration: an updated review.Nanomedicine (London, England) · 2025Review
- A parathyroid hormone related supramolecular peptide for multi-functionalized osteoregeneration.Bioactive materials · 2024Article
- Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems.ACS biomaterials science & engineering · 2023Review
- Novel approaches for periodontal tissue engineering.Genesis (New York, N.Y. : 2000) · 2022Review
- Atomic Force Microscopy (AFM) on Biopolymers and Hydrogels for Biotechnological Applications-Possibilities and Limits.Polymers · 2022Review
- [Local administration of parathyroid hormone and parathyroid hormone-related peptides for bone tissue engineering].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2021Review
- Applications of capillary action in drug delivery.iScience · 2021Review
- Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches.Pharmaceutics · 2020Review
- Biomimetic delivery of signals for bone tissue engineering.Bone research · 2018Article
- Macrophages and skeletal health.Pharmacology & therapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parathyroid hormone (PTH) is the only US Food and Drug Administration (FDA)-approved anabolic agent for the treatment of osteoporosis. The anabolic action of PTH depends on the mode of PTH administration. Pulsatile administration promotes bone formation, however continuous PTH exposure results in bone resorption. In addition, the therapeutic effect of PTH is optimal when the dose and duration fit the therapeutic window. Current PTH treatment requires daily injection, which is neither a convenient nor a favorable choice of patients. Here, an implantable and biodegradable device capable of long-term pulsatile delivery of PTH is developed as a patient-friendly alternative. The advanced materials and fabrication techniques developed in this work enable us to preprogram a pulsatile delivery device to systemically deliver 21 daily pulses of PTH that build bone in vivo. In addition, the device is biodegradable and absorbable in vivo so that no retraction procedure is needed. Therefore, this implantable and biodegradable pulsatile device holds promise to promote bone growth and treat various conditions of bone loss without the burden of daily injections or secondary surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.